AllSci News
LTZ Therapeutics raises USD 38m for myeloid engager immunotherapy pipeline
LTZ Therapeutics, a clinical-stage immunotherapy company headquartered in Redwood City, California, has closed an oversubscribed USD 38 million financing...
Mount Sinai, Memorial Sloan Kettering explore colorectal cancer immune resistance with quadruple checkpoint combo
Researchers at the Icahn School of Medicine at Mount Sinai in New York, with contributions from Memorial Sloan Kettering Cancer Center, report that a...
CellCentric backed with USD 220m in Series D for myeloma hope inobrodib
Cambridge-based CellCentric has closed an oversubscribed USD 220 million Series D financing round to advance pivotal clinical development of inobrodib, its...
BioOra gains global CAR T-cell therapy rights from Wellington Zhaotai for Atla-cel development
BioOra Limited has signed a binding Heads of Terms agreement with Wellington Zhaotai Therapies Limited granting BioOra exclusive rights to develop and...
Avalo picks up USD 375m via share offering to support IL-1beta development
Wayne, Pennsylvania-based Avalo Therapeutics (Nasdaq: AVTX) announced the pricing of an underwritten public offering totaling USD 375 million in gross...
Hoth Therapeutics' HT-001 shows efficacy for EGFR inhibitor-associated dermatologic toxicities in Phase IIa trial
Hoth Therapeutics reported interim Phase IIa results for HT-001 in cancer patients experiencing EGFR inhibitor-associated dermatologic toxicities, according...
Kali Therapeutics' CD19 × CD3 bispecific T-cell engager KT502 ready for Phase I in rheumatoid arthritis
Kali Therapeutics has initiated a first-in-human Phase I trial of KT502, a CD19 × CD3 bispecific T-cell engager administered subcutaneously, in adults with...
Fosun/Teva's anti-PD-1/IL-2 fusion protein FXB0871 to enter the clinic in China for PD-(L)1-resistant solid tumors
A first-in-human (FIH) clinical trial of FXB0871 (TEV-56278), an anti-PD-1/IL-2 antibody-cytokine fusion protein, has been registered in China, with HKEX-...
Cenna Biosciences' amyloid beta-targeting peptide 8M2D enters Phase I/b trial for early Alzheimer's disease
Cenna Biosciences is moving its synthetic peptide 8M2D — also referred to as Nubytide™ in prior company disclosures and as P8 in earlier academic literature...
Epicrispr and Forge Biologics partner on AAV manufacturing for EPI-321 FSHD gene therapy
Epicrispr Biotechnologies and Forge Biologics have announced an AAV manufacturing partnership to support the clinical development of EPI-321, an investigational gene therapy…
Abivax raises USD 45m in share offering for royalty repurchase
France-based Abivax SA (Nasdaq/Euronext Paris: ABVX) announced the pricing of a USD 45 million (EUR 38.5 million) offering of American Depositary Shares to...
Signadori Bio closes EUR 11.1m seed extension to advance monocyte engineering platform
Paris-based Signadori Bio SAS has closed a EUR 11.1 million seed extension round to advance its in vivo monocyte engineering platform for solid tumours,...
Bayer to acquire Perfuse Therapeutics for USD 2.45b to expand ophthalmology pipeline with PER-001
Bayer has agreed to acquire South San Francisco-based Perfuse Therapeutics, Inc. for a total potential value of up to USD 2.45 billion, comprising a USD 300...
Clearmind seeks European patent for non-hallucinogenic neuroplastogen PTSD compounds
Clearmind Medicine Inc. (Vancouver, Canada), a clinical-stage biotech focused on neuroplastogen therapeutics, announced the filing of a European patent application covering novel…
ZYUS Life Sciences receives USPTO patent for cannabichromene pain management formulation
ZYUS Life Sciences Corporation (Canada), a clinical-stage company listed on the TSXV under the ticker ZYUS, received US Patent No. 12,616,704 from…
The AllSci Brief
Systematic R&D and deal news. Daily.